Thymalin® (Lyophilisate) Instructions for Use
Marketing Authorization Holder
Samson-Med LLC (Russia)
ATC Code
L03AX (Other immunostimulants)
Active Substance
Thymus extract (Grouping name)
Dosage Form
| Thymalin® | Lyophilisate for the preparation of solution for intramuscular administration 10 mg: vial 5 or 10 pcs. |
Dosage Form, Packaging, and Composition
Lyophilisate for the preparation of solution for intramuscular administration in the form of a lyophilized mass in the form of a tablet, whole, partially or completely crumbled, white or white with a yellowish tint; the reconstituted solution is clear, colorless or yellowish in color.
| 1 vial | |
| Thymus extract* | 10 mg |
* obtained from the thymus glands of calves and young cattle under one year of age.
Excipients: glycine – 20 mg.
Glass vials with a capacity of 5 ml (5) – cardboard packs.
Glass vials with a capacity of 5 ml (10) – cardboard packs.
Clinical-Pharmacological Group
Immunostimulating drug
Pharmacotherapeutic Group
Immunostimulants; other immunostimulants
Pharmacological Action
It restores impaired immunological reactivity (regulates the number and ratio of T- and B-lymphocytes and their subpopulations, stimulates cellular immune responses, enhances phagocytosis), stimulates regeneration and hematopoiesis processes when they are suppressed, and also improves the course of cellular metabolism processes.
Indications
Immunodeficiency states in adults and children aged from 6 months to 14 years with
- Infectious purulent and septic processes;
- Persistent impairment of thymus function (radiation sickness, neoplastic processes of the thymus, surgical removal of the thymus);
- Acute and chronic viral and bacterial infections;
- Impaired regenerative processes;
- Suppression of immunity and hematopoiesis after chemotherapy or radiation therapy in patients with oncological diseases.
ICD codes
| ICD-10 code | Indication |
| A41 | Other sepsis |
| A49 | Bacterial infection of unspecified site |
| B34 | Viral infection of unspecified site |
| C37 | Malignant neoplasm of thymus |
| D46.9 | Myelodysplastic syndrome, unspecified |
| D84.9 | Immunodeficiency, unspecified |
| E32.9 | Disease of thymus, unspecified |
| T66 | Unspecified effects of radiation (radiation sickness) |
| T79.3 | Posttraumatic wound infection, not elsewhere classified |
| Y83.6 | Surgical operation with removal of other organ (partial) (total) as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure |
| Y84.2 | Radiological procedure and radiotherapy |
| Z98.8 | Other specified postprocedural states |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Administered intramuscularly daily in the following doses: adults 5-20 mg (30-100 mg per course), children aged from 6 months to 1 year – 1 mg; children aged 1-3 years – 1.5-2 mg; children aged 4-6 years – 2-3 mg; children aged 7-14 years – 3-5 mg for 3-10 days depending on the severity of immune disorders.
If necessary, a repeat course is conducted (after 1-6 months).
For prophylactic purposes, it is used intramuscularly daily, adults 5-10 mg, children – 1-5 mg for 3-5 days.
Data on dosing features in patients with impaired renal function, hepatic function, elderly patients are not available.
Adverse Reactions
Possible allergic reactions.
Contraindications
- Hypersensitivity to the active substance or excipients of the drug used;
- Pregnancy;
- Period of breastfeeding.
With caution
Patients with a burdened allergic history.
Use in Pregnancy and Lactation
Contraindicated for use during pregnancy and the period of breastfeeding.
Pediatric Use
Used in children aged from 6 months.
Special Precautions
A relative contraindication to the use of drugs based on peptides isolated from the thymus of cattle is the perimenstrual period, some endocrine syndromes (pituitary adenoma, acromegaly).
The use of drugs based on peptides isolated from the thymus of cattle in patients with severe endocrine disorders and in women in the second phase of the menstrual cycle may more often cause side effects.
It is not recommended to consume alcoholic beverages during the use of the drug.
Influence on the ability to drive vehicles and mechanisms
The use of the drug does not affect the ability to perform potentially hazardous activities requiring increased concentration and speed of psychomotor reactions (driving vehicles, working with moving mechanisms, work of a dispatcher, operator).
Drug Interactions
Thymus extract is compatible with isoniazid, immunostimulating drugs, glucocorticoid drugs, rifampicin, and analgesics.
Simultaneous use of drugs with a mechanism of action similar to this agent should be avoided. Synergism with some pituitary hormones (GH, LH) and with estrogens is possible.
The action of this agent is antagonistic to the effects of progestins, androgens, and adrenal hormones in terms of their influence on the lymphatic system and bone marrow.
Storage Conditions
Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Rx Only
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical Disclaimer